EGRX Insider Trading Activity and SEC Form 4 Filings
EGRX insider trading summary
No open-market insider purchases or sales of Eagle Pharmaceuticals, Inc. (EGRX) have been reported on SEC Form 4 in the past 12 months.
Latest EGRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 2, 2023 | Scott Tarriff | CEO | Sell | $148K (10,694 @ $13.87) |
| Nov 1, 2023 | Scott Tarriff | CEO | Sell | $151K (10,925 @ $13.82) |
| Oct 3, 2023 | Scott Tarriff | CEO | Sell | $144K (10,024 @ $14.41) |
| Oct 3, 2023 | Scott Tarriff | CEO | Sell | $11K (710 @ $15.11) |
| Oct 2, 2023 | Scott Tarriff | CEO | Sell | $145K (9,511 @ $15.23) |
| May 16, 2023 | Scott Tarriff | CEO | Sell | $300K (15,000 @ $19.98) |
| May 15, 2023 | Scott Tarriff | CEO | Sell | $4K (200 @ $21.52) |
| May 15, 2023 | Scott Tarriff | CEO | Sell | $312K (14,800 @ $21.06) |
| May 12, 2023 | Scott Tarriff | CEO | Sell | $242K (11,869 @ $20.42) |
| May 12, 2023 | Scott Tarriff | CEO | Sell | $62K (3,131 @ $19.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.